Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.
about
Patient Burden of Axial Spondyloarthritis.Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2.Recent advances in ankylosing spondylitis: understanding the disease and managementThe Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and FutureThe role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis
P2860
Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Secukinumab and Sustained Impr ...... esults From a Phase III Study.
@en
type
label
Secukinumab and Sustained Impr ...... esults From a Phase III Study.
@en
prefLabel
Secukinumab and Sustained Impr ...... esults From a Phase III Study.
@en
P2093
P2860
P356
P1476
Secukinumab and Sustained Impr ...... esults From a Phase III Study.
@en
P2093
H B Richards
Measure 2 Study Group
P2860
P304
P356
10.1002/ACR.23233
P577
2017-02-24T00:00:00Z